It would facilitate the timely initiation of treatment for a clear diagnosis of the disease, but also helps to reasonably evaluate the prognosis and disease progression of patients so that clinicians can formulate first-line strategies, rationally use drugs, and accumulate practical treatment experience for CML with rare BCR::ABL fusion genes. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.